Ectodomain Shedding by ADAM17 Increases the Release of Soluble CD40 from Human Endothelial Cells under Pro-Inflammatory Conditions

Cells. 2023 Jul 25;12(15):1926. doi: 10.3390/cells12151926.

Abstract

Background: Homozygosity for the C allele of the -1T>C single nucleotide polymorphism (SNP) of the CD40 gene (rs1883832) is associated with susceptibility to coronary heart disease (CHD), enhanced CD40 expression, and shedding. The disintegrin metalloprotease ADAM17 can cleave various cell surface proteins. This study investigates an association between ADAM17-mediated CD40 shedding and inflammation in CC genotype human endothelial cells.

Methods: Human umbilical vein endothelial cells (HUVEC) carrying the CC genotype were stimulated with soluble CD40 ligand (sCD40L) or tumor necrosis factor-α (TNFα). Messenger RNA and protein expression were determined with standard methods. Levels of high sensitive c-reactive protein (hs-CRP), interleukin-6 (IL-6), and sCD40 in plasma samples from patients with CHD were assessed using ELISA.

Results: ADAM17 surface abundance was elevated following stimulation with CD40L and TNFα just as its regulator iRhom2. Inhibition of ADAM17 prevented TNFα-induced sCD40 and soluble vascular cell adhesion molecule-1 release into the conditioned medium and reinforced CD40 surface abundance. Secondary to inhibition of ADAM17, stimulation with CD40L or TNFα upregulated monocyte chemoattractant protein-1 mRNA and protein. Levels of sCD40 and the inflammatory biomarkers hs-CRP and IL-6 were positively correlated in the plasma of patients with CHD.

Conclusions: We provide a mechanism by which membrane-bound CD40 is shed from the endothelial cell surface by ADAM17, boosting sCD40 formation and limiting downstream CD40 signaling. Soluble CD40 may represent a robust biomarker for CHD, especially in conjunction with homozygosity for the C allele of the -1T>C SNP of the CD40 gene.

Keywords: ADAM17; biomarker; endothelial cells; single nucleotide polymorphism; soluble CD40.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADAM17 Protein* / genetics
  • C-Reactive Protein
  • CD40 Antigens* / metabolism
  • CD40 Ligand / pharmacology
  • Human Umbilical Vein Endothelial Cells / metabolism
  • Humans
  • Interleukin-6
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • ADAM17 Protein
  • ADAM17 protein, human
  • C-Reactive Protein
  • CD40 Antigens
  • CD40 Ligand
  • Interleukin-6
  • Tumor Necrosis Factor-alpha

Grants and funding

This work was supported by intramural funds allocated to Markus Hecker. Anton Klersy was supported by a doctoral scholarship from the German Cardiac Society (Otto-Hess-Promotionsstipendium). Thorsten Kessler was supported by the Corona Foundation (Junior Research Group Translational Cardiovascular Genomics), the German Research Foundation (SFB 1123, project B2; research project KE2116/4-1), and the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (ERC Starting Grant MATRICARD).